Medical and Pharmaceutical Industry - Market Research Report

  The global minimally invasive surgical instruments market size is expected to reach USD 63.0 billion by 2030, registering a CAGR of 10.4% during the forecast period, according to a new report by Grand View Research, Inc. The preference for minimally invasive surgical (MIS) procedures is rising as they are less traumatic than traditional open surgeries and they facilitate faster recover process. Patients can resume their daily activities in a shorter time after minimally invasive surgical procedures. In addition, the costs involved in MIS procedures are significantly less than in-patient and conventional open surgeries. Therefore, MIS procedures prove to be beneficial for patients as well as payers. The benefits of MIS in various areas of orthopedics have contributed to the growing demand for less traumatic alternatives with minimum tissue disruption of bones. Noncommunicable Diseases (NCDs), often known as chronic diseases, affect more than 41 million individuals each year, accou...

  The global restorative dentistry market size is expected to reach USD 34.8 billion by 2030, registering a CAGR of 7.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the restorative dentistry market is attributed to the improved quality of services offered and the availability of large patient pool. Moreover, innovation in implants & prosthetics, increasing demand for cosmetic dentistry, and growth of dental tourism is expected to fuel market growth in the forecast period. The COVID-19 pandemic has adversely affected the dental market in 2020. According to the WHO guidelines, viral infection mainly spreads through the eyes, nose, and mouth which makes it difficult for the dentist to operate on patients during such times. Routine cleaning, orthodontic procedures, preventive therapies, and oral examinations that do not involve pain management were postponed during the COVID-19 pandemic thus negatively impacting the restorative dentistry ...

  The global cell expansion market size is expected to reach USD 47.13 billion by 2030 registering a CAGR of 12.85%, according to a new report by Grand View Research, Inc. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies. Therefore, significant developments in cord blood SCs expansion technologies are expected to boost market growth. Companies have made heavy investments for the expansion of tissue-engineered products and the development of biologics. For instance, in March 2019, Merck KGaA invested USD 168 million for the expansion of its biologics manufacturing facility in Switzerland. Such initiatives are expected to boost the demand for solutions required for biologic development, thereby leading to market growth. Gather more insights about the market drivers, restrains a...

  The global medical tubing market size is anticipated to reach USD 19.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.5% from 2024 to 2030. The prevalence of respiratory diseases such as asthma, lung cancer, and pulmonary fibrosis worldwide is anticipated to fuel the global demand for medical tubing, as it is essential component of respiratory devices such as ventilators and nebulizers. Growing awareness among the masses about hospital-acquired diseases and surging concerns about the spread of such infections are projected to drive demand for disposable medical devices. According to the World Health Organization (WHO), the incidences of ICU-acquired infections are 2 to 3 times higher in low- and middle-income countries than in high-income countries, while device-associated infections are approximately 13 times higher in these countries than in the U.S. Governments, predominantly in emerging economies, are in...

The global defibrillator market size is expected to reach USD 12.57 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 8.1% from 2024 to 2030. The key drivers for this market include supportive regulatory policies, rising incidences of sudden cardiac arrests, product developments, and rising awareness regarding cardiac conditions. The COVID-19 pandemic, however, gave rise to several challenges such as dampened demand for ICDs, logistical bottlenecks, postponed elective surgeries across the globe, and reduced sales growth. The demand for ICDs plunged during 2020 as governments in many key markets implemented movement restrictions and hospitals deferred elective procedures. The sales recovered gradually as movement restrictions were eased and elective procedure volume went up. For instance, Abbott reported a decline in demand and sales of its cardiovascular and neuromodulation portfolio in 2020. Abbott attributed the sales ...

The global oral solid dosage (OSD) contract manufacturing market was valued at USD 36.50 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030. The market's growth is fueled by advancements in drug delivery technologies, including targeted drug delivery and sustained-release dosage forms. Additionally, contract development manufacturing organizations (CDMOs) are heavily investing in expanding capabilities for oral solid dosage development, driven by the rising demand for novel therapies. The replacement of conventional oral pharmaceutical products with emerging technologies is becoming increasingly likely. For example, the integration of 3D printing in OSD manufacturing offers precise control over drug release and the ability to customize dosage forms tailored to individual patient needs. This technology facilitates the creation of complex shapes and formulations, providing flexibility in drug design and manufacturing. Conseque...

The global pharmaceutical CDMO (Contract Development and Manufacturing Organization) market was valued at USD 146.0 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% between 2024 and 2030. This growth is primarily driven by increasing investments in drug development by CDMOs and the rising demand for novel therapies. Other key contributors include heightened pharmaceutical R&D spending, growing demand for genetic drugs, the prevalence of cancer and age-related disorders, and the escalating need for advanced therapeutic solutions. Additionally, the increasing adoption of biosimilars, biologics, personalized medicine, orphan drugs, companion diagnostics, and adaptive trial designs is further fueling demand for CDMO services. As pharmaceutical companies push the boundaries of innovation, the necessity to comply with stringent regulations is intensifying the reliance on specialized CDMO providers adept at navigating complex development and manufac...